We further evaluated the relationships between MKK7 p.Glu116Lys and lung cancer progression, and found that p.Glu116Lys was significantly associated with pejorative clinical stages (P <0.001, shown in S1 Table). The gene discussed is MAP2K7; the disease is lung carcinoma.